PMID- 38520616
OWN - NLM
STAT- Publisher
LR  - 20240323
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2024 Mar 23
TI  - Retinol binding protein 4 and type 2 diabetes: from insulin resistance to 
      pancreatic beta-cell function.
LID - 10.1007/s12020-024-03777-5 [doi]
AB  - BACKGROUND AND AIM: Retinol binding protein 4 (RBP4) is an adipokine that has 
      been explored as a key biomarker of type 2 diabetes mellitus (T2DM) in recent 
      years. Researchers have conducted a series of experiments to understand the 
      interplay between RBP4 and T2DM, including its role in insulin resistance and 
      pancreatic beta-cell function. The results of these studies indicate that RBP4 has a 
      significant influence on T2DM and is considered a potential biomarker of T2DM. 
      However, there have also been some controversies about the relationship between 
      RBP4 levels and T2DM. In this review, we update and summarize recent studies 
      focused on the relationship between RBP4 and T2DM and its role in insulin 
      resistance and pancreatic beta-cell function to clarify the existing controversy and 
      provide evidence for future studies. We also assessed the potential therapeutic 
      applications of RBP4 in treating T2DM. METHODS: A narrative review. RESULTS: 
      Overall, there were significant associations between RBP4 levels, insulin 
      resistance, pancreatic beta-cell function, and T2DM. CONCLUSIONS: More mechanistic 
      studies are needed to determine the role of RBP4 in the onset of T2DM, especially 
      in terms of pancreatic beta-cell function. In addition, further studies are required 
      to evaluate the effects of drug intervention, lifestyle intervention, and 
      bariatric surgery on RBP4 levels to control T2DM and the role of reducing RBP4 
      levels in improving insulin sensitivity and pancreatic beta-cell function.
CI  - (c) 2024. The Author(s).
FAU - Fan, Jiahua
AU  - Fan J
AUID- ORCID: 0000-0002-1629-3034
AD  - State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of 
      Tuberculosis Research, Department of Clinical Nutrition, Guangzhou Chest 
      Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangzhou, 
      510095, Guangdong, PR China. fanjh3@mail2.sysu.edu.cn.
FAU - Hu, Jinxing
AU  - Hu J
AD  - State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of 
      Tuberculosis Research, Department of Tuberculosis, Guangzhou Chest Hospital, 
      Institute of Tuberculosis, Guangzhou Medical University, Guangzhou, 510095, 
      Guangdong, PR China.
LA  - eng
GR  - 2019A1515110583/Guangdong Basic and Applied Basic Research Fund Project (Regional 
      Joint Fund-Youth Fund Project)/
GR  - 2019A1515110583/Guangdong Basic and Applied Basic Research Fund Project (Regional 
      Joint Fund-Youth Fund Project)/
PT  - Journal Article
PT  - Review
DEP - 20240323
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
SB  - IM
OTO - NOTNLM
OT  - Insulin resistance
OT  - Pancreatic beta-cell function
OT  - Retinol binding protein 4
OT  - Type 2 diabetes
EDAT- 2024/03/23 20:51
MHDA- 2024/03/23 20:51
CRDT- 2024/03/23 12:20
PHST- 2023/09/22 00:00 [received]
PHST- 2024/03/01 00:00 [accepted]
PHST- 2024/03/23 20:51 [medline]
PHST- 2024/03/23 20:51 [pubmed]
PHST- 2024/03/23 12:20 [entrez]
AID - 10.1007/s12020-024-03777-5 [pii]
AID - 10.1007/s12020-024-03777-5 [doi]
PST - aheadofprint
SO  - Endocrine. 2024 Mar 23. doi: 10.1007/s12020-024-03777-5.